Novartis' (NVS) multiple sclerosis pill, Gilenya, lost marketshare for the first time ever in...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS) multiple sclerosis pill, Gilenya, lost marketshare for the first time ever in January after 15 months of growth. The FDA and European regulators are investigating 11 deaths among Gilenya patients, prompting caution from both doctors and analysts. (previously)